Clinical Trial Search

Primary: Percentage of Patients With Clearing (Clinical Success) of Conjunctival Erythema and Conjunctival Discharge at Day 7 — 78.6; 84.4 Percentage of Patients

Primary: Change From Baseline in Global Ocular Staining Score at Day 35 — 5.4; 5.9; -1.8; -1.8 Number on a scale (score)

Primary: Percentage of Pregnant Patients After IVF Treatments — 66; 62 percentage of participants — p=<0.05

Primary: Incidence of Diarrhea — 201; 204; 260; 224 episodes

Primary: Total Volume of Colloid Solution Required Intraoperatively — 36.6; 36.97 ml/kg

Primary: Patient's Perception of Pain Using the Wong-Baker FACES Visual Scale: 0 - no Pain; 5 - Worst Imaginable Pain — 1; 2 Scores on a scale — p=<0.001

Primary: Laboratory-confirmed (Culture and/or PCR) Symptomatic Influenza — 28; 56; 35 participants

Primary: CSL's IVV Overall Vaccine Efficacy (VE) Versus Placebo Through Assessment of Incidence of Laboratory Confirmed Influenza A/B Infection — 2.24; 3.87 Ratio

Primary: The Time to Return to Baseline Platelet Function as Assessed by P2Y12 Reaction Units (PRU) Using the Accumetrics VerifyNOW P2Y12 Device Based on the Primary Definition…

Primary: Seizure Reduction Rate — -16.35 Percentage of Seizure Reduction Rate

Primary: Yale Global Tic Severity Scale (YGTSS): — 45.2; 48.7; 48.8; 43.1 scores on a scale

Primary: Time to Loss of Therapeutic Response (LTR) — 56; NA Days — p=0.0004

Primary: The Changes of Middle Cerebral Artery (MCA) and Basilar Artery (BA) Pulsatility Index (PI) at 14 and 90 Days From the Baseline Transcranial Doppler (TCD) Study — 0.07…

Primary: Peak Low Molecular Weight Heparin Anti-Xa Activity Level. — 0.25 IU/mL

Primary: Number of Participants With Fever Post Dose 1 (Days 1-8), Defined as an Oral Temperature ≥ 101°F (38.3°C). — 0; 0 Participants